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Fibroblast growth factor receptors (FGFRs) play critical roles in craniofacial and skeletal development
via multiple signaling pathways including MAPK, PI3K/AKT, and PLC-c. FGFR-mediated signaling is
modulated by several regulators. Proteins with leucine-rich repeat (LRR) and/or immunoglobulin
(IG) superfamily domains have been suggested to interact with FGFRs. In addition, ﬁbronectin
leucine-rich repeat transmembrane protein 3 (FLRT3) has been shown to modulate the FGFR-medi-
ated signaling via the ﬁbronectin type III (FNIII) domain. Therefore proteins with LRR, IG, and FNIII
are candidate regulators of the FGFRs. Here we identify leucine-rich repeat, immunoglobulin-like
and transmembrane domain 3 (LRIT3) as a regulator of the FGFRs.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Fibroblast growth factor (FGF)-signaling plays crucial roles in
cell proliferation and differentiation. FGFs activate the different
isoforms of the FGF receptors (FGFR1, 2, 3 and 4) [1]. All FGFRs
are type I membrane proteins that are synthesized in the endoplas-
mic reticulum (ER). Heparin or heparan sulfate forms a bridge be-
tween FGF and FGFR and is necessary for efﬁcient FGF-signaling
[2]. Upon exposure to FGF, FGFR dimerizes, resulting in activation
of the tyrosine kinase (TK) activity and transautophosphorylation
of tyrosine residues on the intracellular portion of the receptor
[3]. Phosphorylated FGFR activates a variety of cellular signaling
pathways including the mitogen-activated protein kinase (MAPK),
PLC-c, and PI3K/AKT [1,4,5].
Missense mutations or ampliﬁcation of FGFR have been impli-
cated in cancer as well as in other developmental diseases includ-
ing craniosynostosis (CS), or premature fusion of cranial sutureschemical Societies. Published by E
etics, Department of Pediat-
25, 50th Street, The M.I.N.D.,
yadjiev); Section of Genetics,
is Medical Center, 2805, 50th
acramento, CA, USA. Fax: +1
vis.edu (S.A. Boyadjiev),[1,6]. Especially, gain-of-function mutations of FGFR cause syn-
dromic craniosynostosis (SC) where CS is associated with other
developmental anomalies and inherited in a Mendelian fashion
[7–9]. However, SC only accounts for a small fraction of CS cases
and the majority of CS cases occur as sporadic ﬁndings without
other associated anomalies [10]. Considering the major impact of
aberrant FGF-signaling in SC, it is possible that some NSC cases
are caused by alterations in proteins that regulate or mediate
FGF-signaling.
Multiple cellular factors such as Sprouty (SPRY), MAP kinase
phosphatase 3 (MKP3), Similar Expression to FGFs (SEF), and
ﬁbronectin-leucine-rich transmembrane protein 3 (FLRT3) have
been shown to regulate the FGF-signaling pathway [11–13]. In
addition, a recent study has shown that proteins with leucine-rich
repeat (LRR) and/or immunoglobulin (IG) superfamily domains
may interact with FGFRs [14]. In the case of FLRT3, interaction with
FGFR1 is via its ﬁbronectin type III (FNIII) domain and activation of
the MAPK signaling pathway [13]. Thus, families of proteins with
FNIII, LRR, and IG domains may serve as regulators of FGFRs and
other growth factor receptors.
We sought to identify new regulators of FGFR1. We focused on
ﬁbronectin leucine-rich repeat transmembrane protein 3 (LRIT3)
as it contains the suggested domains for FGFR interaction. Our re-
sults suggest that LRIT3 regulates maturation and signaling of
FGFR1.lsevier B.V. All rights reserved.
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2.1. Antibodies
The following antibodies were used for immunoblotting: Mouse
anti-Myc (Millipore, USA; 1/1000), rabbit anti-beta-tubulin (Cell
signaling Tech, USA, 1/1000), rabbit anti-phospho-ERK (Cell signal-
ing Tech, USA, 1/1000), rabbit anti-ERK (Cell signaling Tech, USA, 1/
1000), mouse anti-LRIT-3 (Novus Bioscience, USA, 1/1000), rabbit
anti-phospho-AKT (Cell signaling Tech, USA, 1/1000), rabbit anti-
AKT (Cell signaling Tech, USA, 1/1000), rabbit anti-PLC-c (Cell
signaling Tech, USA, 1/1000), rabbit anti-phospho-PLC-c (Cell
signaling Tech, USA, 1/1000), anti-rabbit IgG conjugated with horse
radish peroxidase (Amersham Bioscience, USA, 1/5000), rabbit
anti-FGFR1 (Cell signaling Tech, USA, 1/1000).
2.2. Subjects and clinical data
Informed consent was obtained from all patients and/or their
parents. This study was approved by the Institutional Review
Boards of the University of California, Davis, and was conducted
in accordance with institutional guidelines.
2.3. PCR, DNA sequencing, and sequence analyses
A total of 431 individuals with non-syndromic craniosynostosis
were selected for sequencing of LRIT3. Peripheral blood or saliva
samples were collected from individuals, and genomic DNA was
isolated as per conventional protocols with PureGene (5 Prime
Inc.) or Oragene (Nalgene). LRIT3 exons were ampliﬁed by polymer-
ase chain reactions. PCR products were puriﬁed with Shrimp Alka-
line Phosphatase and Exonuclease I (USB Corporation, Cleveland,
OH). PCR primers are available in Table S1. Puriﬁed DNA fragments
were sent to UC Davis Sequencing Facility and electropherograms
were analyzed with VectorNTI™ Version 11 computer program.
The 50- and 30-untranslated regions of LRIT3, as well as at least
100 base pairs of ﬂanking intronic sequence for each exon were
included in the sequencing analysis. The observed variants were
conﬁrmed by independent PCRs and sequencing of the reverse
DNA strands. Parental samples (when available) were sequenced.
Single nucleotide polymorphisms (SNPs) were considered novel if
not described in the NCBI SNP database.
2.4. Taqman assays
Five Custom TaqMan SNP Genotyping Assays manufactured by
Applied Biosystems were designed to detect the novel polymorphic
variants on Human Random Control DNA Panels 1–5 (European
Collection of Cell Cultures, kind gifts from Michael L. Cunningham,
University of Washington) using the ABI 7900HT QPCR machine.
QPCR primers, probes, and conditions are available upon request.
Allelic Discrimination was performed to classify the zygosities of
the targeted templates by analyzing the ﬂuorescence signals in
each reaction well.
2.5. Construction of a human calvarial osteoblast cDNA library
Total RNA from human calvarial osteoblasts was isolated using
Trizol reagent (Invitrogen, USA) RNA extraction reagent. cDNA was
synthesized from 1 lg of total RNA using SuperScript First-Strand
Synthesis System for RT-PCR (Invitrogen, USA). The DNA fragment
containing the new exon 1 and a part of the previously known exon
1 of human LRIT3was ampliﬁed using osteoblast cDNA library with
following synthetic oligonucleotide pairs (forward, 50-ATGCATCTC
TTTGCATGTCTGTGC-30; reverse, 50-CACGGGGAGGTTCGTAGGCAGCTCGTTCATATC-30). The PCR product was conﬁrmed by DNA
sequencing.
2.6. Cell culture and transient transfection
The HEK 293T cells were cultured in DMEM media containing
10% fetal bovine serum andmaintained in a water-jacketed incuba-
tor at 37 Cwith5%CO2 enrichment (Boydet al., 2006). Sub-cultured
cells weremaintained in DMEMmedia with 10% fetal bovine serum
and split 1:5 weekly or when conﬂuent. The plasmid DNAs were
transiently transfected into HEK 293T cells using Lipofectamine
and Plus according to themanufacturer’s protocol (Invitrogen, USA).
2.7. Immunoblotting
Cells were washed in cold PBS and lysed in radioimmunoprecip-
itation assay buffer (25 mM Tris–HCl, pH7.6, 150 mM NaCl, 1% NP-
40, 0.1% sodium dodecyl sulfate, 1% sodium deoxycholate and
5 mM EDTA) containing protease inhibitors (Roche, USA). The pro-
teins concentration of cell lysates was determined with a bicin-
chroninic acid assay according to the manufacturer’s protocol
(Pierce, USA). Protein lysates were resolved in SDS–PAGE, trans-
ferred to PVDF membrane, probed with primary antibodies, incu-
bated with secondary antibodies conjugated with horse radish
peroxidase (HRP), and visualized with ECL plus.
2.8. Site-directed mutagenesis and plasmid construction
The human LRIT3 coding region was ampliﬁed from pCR-Blunt
II-LRIT-3 (Open Biosystems, USA) using synthetic oligonucleotides
pairs (50-GGCTAACTAGAGAACCCACTG-30 and 50-GATTCTAGATTAC
AGGTCCTCCTCTGAGAT-30). The ampliﬁed fragments were digested
with Nae I and Xba I and inserted into mammalian expression vec-
tor pCMV-SPORT6 (Invitrogen, USA). The resulting plasmid has a
Myc-tag at the C terminus. The mutagenic primers for LRIT3
(T53M, S494T, and C592Y) were as follows: sense LRIT3 T53M,
50-CCCGCTAGCATGGATATGAACGAGCTGCCTATGAACCTC-30; anti-
sense LRIT3 T53M, 50-GAGGTTCATAGG CAGCTCGTTCATATCCATGC-
TAGCGGG-30; sense LRIT3 S494T, 50-GCAATAGAAAACCTCAGGGT
GGTCACTGAGACTAAAG-30; antisense LRIT3 S494T 50-CGTCAATGT-
CACACTCT CTTTAGTCTCAGTGACCAC-30; sense LRIT3 C592Y 50-
GACCAG ACTGCCTATGTTGTTATC-30; antisense LRIT3 C592Y 50-
GATAACAACATA GGCAGTACTGGTC. To incorporate a signal se-
quence for LRIT3, an oligonucleotide (50-ATGCATCTCTTTGCATGTC
TGTGCATTGTCCTTAGCTTTTTGGAAGGAGTGGGCTGTTTGTGTCCTTC
ACAGTGCACCTGTGATTATCACGGCAGAAATGACGGCTCAGGATCAAG
GTTGGTGCTATGTAATGAC-30) was used. The sequence was con-
ﬁrmed by DNA sequencing.
2.9. Deglycosylation experiments
Cleared cell lysates (30 lg) obtained from transiently transfec-
ted cells with either LRIT3 or FGFR1 or both were heat treated in
1 Glycoprotein Denaturing Buffer at 100 C for 10 min according
to the manufacturer’s instructions (New England Biolabs Inc, Bev-
erly, MA, USA). The denatured proteins were treated with peptide
N glycosidase F (PNGase F) or endoglycosidase H (Endo H) at 37 C
1 h. The resulting proteins were analyzed by immunoblotting after
separation with 10% SDS–PAGE.
3. Results
When we compared the amino terminal sequence of human
LRIT3 with those of the piscine and rodent LRIT3, it was noted that
human LRIT3 lacked a signal sequence and its immediate ﬂanking
1518 S.-D. Kim et al. / FEBS Letters 586 (2012) 1516–1521region (Fig. 1A and B). Simian and bovine LRIT3 also lacked a signal
sequence and its ﬂanking region (Fig. S1A). We reasoned that an
exon(s) encoding these regions must exist in the genomic sequence
of LRIT3 and searched for the exon in the 50 upstream sequence
(about 6 kb) of human LRIT3. We anticipated that the new exon
would encodes a signal sequence and its ﬂanking region that
would be highly homologous to those of rodent LRIT3s. Indeed,
we were able to identify a sequence stretch with such features
approximately 3.3 kb upstream of the previous exon 1 (Fig. 1C).Fig. 1. Identiﬁcation of signal sequence of LRIT3. (A) Comparison of domain structures
immunoglobulin-like, leucin-rich repeat, ﬁbronectin type III, transmembrane, and tyro
database lacks a signal sequence and its ﬂanking sequences compared to rodent and pis
sequence is underlined and the signal peptide cleavage site was predicted by using a pro
represents the putative splicing juncture. (C) A putative exon encoding the signal sequen
genomic sequence. Putative splicing donor and acceptor sequences are underlined. Arg
terminus of LRIT3 is shown. Residues in green are conserved in rodent and human LRIT3s
sequence is underlined. (E) A PCR reaction was performed using a forward primer that ann
generated from human osteoblasts (see Section 2 for detail). An 171 bp-fragment is expe
of the new exon and the exon 1 from the 171 bp-fragment ampliﬁed from the cDNA l
putative splicing juncture.This newly identiﬁed putative exon is bordered by splice acceptor
and donor sequences (AG and GT, respectively) and is in-frame
with the subsequent exon (the previous exon 1). The newly assem-
bled N-terminus of human LRIT3 is highly homologous to those of
rodent LRIT3s (Fig. 1D). Although there may be additional exons for
the 50untranslated region at the 50 upstream of this sequence, we
believe that the complete N-terminal polypeptide sequence of
LRIT3 is encoded in this new exon because the current sequence
shows typical characteristics of a signal sequence [15,16].of FGFR1, FLRT3 and LRIT3. SS, IG, LRR, FNIII, TM, and TK denote signal sequence,
sine kinase domains, respectively. (B) Human LIRT3 (NP_940908.2) from the NCBI
cine LRIT3s (XP_143529.7, XP_578083.3, and NP_001139102.1). The putative signal
gram, SignalP 3.0 (http://www.cbs.dtu.dk/services/SignalP/). Arginine shown in red
ce and the early mature region was found at the 50-upstream of LRIT3 from human
inine shown in red represents the putative splicing juncture. (D) The proposed N-
. Arginine shown in red represents the putative splicing juncture. The putative signal
eals at the new exon, a reverse primer that anneals at the exon 1, and a cDNA library
cted to be ampliﬁed from this reaction. (F) Chromatogram near the splicing juncture
ibrary. Amino acid sequences are italicized. Arginine shown in red represents the
Fig. 2. LRIT3 inﬂuences the stability and glycosylation of FGFR1. (A) HEK293 cells
were transfected with FGFR1 and LRIT3 as indicated. The transfected cells were
analyzed by immunoblotting. b-Tubulin was also probed as a loading control. A
mouse monoclonal anti-LRIT3 antibody was used to visualize LRIT3. Note that
endogenous FGFR1 and LRIT3 are not detectable in HEK cells under our conditions.
(B) The LRIT3/FGFR1-transfected HEK293 cells were lyzed in RIPA buffer and
treated with Endo H or PNGase F. A mouse monoclonal anti-LRIT3 antibody was
used to visualize LRIT3. LRIT3 became unstable during deglycoyslation procedure
and difﬁcult to detect. LRIT3 was detectable only in lanes 7 to 9. (C) HEK293
cells transfected with the indicated plasmid constructs were incubated with or
without bFGF1 for 30 min. An anti-Myc antibody was used to visualize LRIT3. The
anti-Myc antibody also labels a non-speciﬁc band (asterisk) above the LRIT3 band
position.
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quence, we designed a primer pair for the new exon (a forward pri-
mer) and the previously known exon1 (a reverse primer) that can
amplify the portion of the spliced form (171 bp). Using this primer
pair and a cDNA library generated from human calvarial osteo-
blasts, we were able to amplify the expected 171 bp fragment
and to verify its sequence (Fig. 1E and F). This result shows that
the human LRIT3 also contains a signal sequence and its ﬂanking
sequence that are highly homologous to those of the rodent LRIT3s.
In addition, we were able to identify the equivalent sequences for
simian and bovine LRIT3s from their genomic sequences (Fig. S1 B
and C). The nucleotide sequence of this new human LRIT3 has been
deposited into the GenBank database (accession number:
JQ354981).
When LRIT3 and FGFR1 were expressed in HEK293 cells, two
interesting observations were made. Firstly, when they were co-
expressed, the levels of the two proteins were increased compared
to those of individual expression (Fig. 2A, compare LRIT3 in lane 3
with that in lane 6; compare FGFR1 in lane 4 with that in lane 5 or
6). The increase in the levels of FGFR1 was more pronounced than
the increase in the levels of LRIT3. Secondly, the slowly migrating
FGFR1 species was enhanced when LRIT3 was present. FGFR1 is
N-glycosylated and exists as Golgi-modiﬁed and ER-modiﬁed
forms [17]. The enhancement of the slowly migrating FGFR1 spe-
cies likely represents an increase in Golgi-modiﬁed forms. To cor-
roborate this possibility, HEK293 cells were transfected with
LRIT3 and/or FGFR1 and the resulting cell lysates were treated with
endoglycosidase H (Endo H) and peptide N-glycosidase F (PNGase
F) (Fig. 2B). Endo H removes N-glycans from ER-modiﬁed forms
and PNGase F removes N-glycans from ER-modiﬁed forms as well
as from Golgi-modiﬁed forms. As expected, the slowly migrating
FGFR1 species was Endo H-resistant and PNGase F-sensitive, indi-
cating that LRIT3 enhances Golgi-modiﬁed forms of FGFR1. Sur-
prisingly, LRIT3 existed predominantly as ER-modiﬁed forms.
These results suggest that LRIT3 facilitates exit of FGFR1 from the
ER.
We then expected that the increase in Golgi-modiﬁed forms of
FGFR1 results in enhancement in FGF-signaling (Fig. 2C). Expres-
sion of FGFR1 alone induced robust phosphorylation of ERK1/2
when the cells were treated with bFGF1 (Fig. 2C, compare lane 3
with lane 4). However, we did not detect enhanced phosphoryla-
tion of AKT nor phosphorylated PLC-c in the presence of bFGF1.
Coexpression of FGFR1 and LRIT3 did not cause an additional in-
crease in phosphorylation of ERK1/2 compared to expression of
FGFR1 alone (Fig. 2C, compare lane 4 with lane 8). It is likely that
even when FGFR1 is expressed alone this amount of FGFR1 (ER
forms or Golgi forms) can efﬁciently saturate the capacity of the
cells to phosphorylate ERK1/2. Thus, more Golgi-modiﬁed forms
of FGFR1 may not cause additional increase in the ERK1/2 phos-
phorylation. In addition, we did not observe any change in phos-
phorylation of AKT by LRIT3 expression. Interestingly, however,
phosphorylation of PLC-c was detectable when FGFR1 and LRIT3
were coexpressed. However, phosphorylation of PLC-c was not
dependent on bFGF1. These results suggest that LRIT3 can aber-
rantly activate the PLC-c branch of the FGFR1-signaling pathway.
Over-activation of FGFR has been implicated in syndromic CS
[18,19]. Furthermore, constitutive RTK-PLC-c signaling has been
also implicated in murine CS [20]. Thus, it seemed reasonable to
propose that LRIT3 mutations that can aberrantly modulate
FGFR1-signaling might also be found in patients with NSC. We
therefore sequenced all coding exons of LRIT3 in more than 400
NSC patients and identiﬁed two probands with sagittal NSC with
previously unreported LRIT3 mutations: S494T (S449T, based on
the previous numbering) and C592Y (C547Y, based on the previous
numbering) (Fig. 3A). These residues are highly conserved (Fig. 3B)
and not present in either in 400 control chromosomes nor reportedamong the more than 10,700 alleles of LRIT3 reported in the Uni-
versity of Washington Exome Variant Server (http://evs.gs.
washington.edu/EVS/). The S494 residue is located in the FNIII do-
main, and the C592 residue in the TM domain (Fig. 3C). It is note-
worthy that the FNIII domain of FLRT3 is implicated in FGFR1
interaction [21].
We then tested whether these mutations affect FGF-signaling
(Fig. 4). We also generated a T53M (previously known as T8M)
LRIT3 construct as a control. This is a known variant that may or
may not alter the function of LRIT3. All LRIT3 variants stabilized
FGFR1 and increased Golgi-modifed forms of FGFR1 just like
wild-type LRIT3 (Fig. 4A). This result suggests that these mutations
Fig. 3. Identiﬁcation of rare LRIT3 mutations from a cohort of non-syndromic CS patients. (A) Two rare mutations of LRIT3 were found from DNA samples of more than 200
non-syndromic sagittal CS patients. Chromatograms show the altered bases (underlined). Note that numbering of the LRIT3 residues is according to the new sequence in
Fig. 1. Previous numbering is shown in parenthesis. (B) The affected positions are highly conserved in vertebrates (arrowheads). Absolutely conserved sequences were shown
in red and the residues conserved in ﬁve species in green. The Clustal W analysis was performed using LRIT3 sequences from NP_940908.2 (Homo sapiens), XP_002815104.1
(Pongo abelii), XP_001088511.1 (Macaca mulatta), DAA28914.1 (Bos taurus), XP_143529.7 (Mus musculus), XP_578083.3 (Rattus norvegicus), and NP_001139102.1 (Danio rerio).
(C) The relative positions of the two mutations identiﬁed from this study were shown in the domain structure of LRIT3 with arrowheads.
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of FGFR1. Mutant LRIT3 did not affect phosphorylation of ERK1/2 or
AKT, compared to wild-type LRIT3. Remarkably, S494T and C592Y
LRIT3 further enhanced phosphorylation of PLC-c than WT or
T53M LRIT3. This increase in PLC-c phosphorylation required
FGFR1. However, phosphorylation of PLC-c was not additionally
stimulated by bFGF1 (Fig. 4B). Thus, we conclude that LRIT3 can
inﬂuence maturation and signaling of FGFR1.
4. Discussion
We have identiﬁed full-length LRIT3, have shown that this
LRIT3 may inﬂuence maturation and signaling of FGFR1 when
over-expressed in cultured cells, and have pinpointed FNIII and
TM of LRIT3 as critical domains for inﬂuencing FGFR1-signaling.
LRIT3 predominantly exists in ER-modiﬁed forms and can increase
the ratio of Golgi-modiﬁed forms to ER-modiﬁed forms of FGFR1.
In particular, we have observed bFGF1-independent activation of
the PLC-c branch of the FGFR-signaling pathway. Perhaps highly
over-expressed FGFR1s can interact and phosphorylate each other
at the cell surface without a ligand [22]. Alternatively, stabilization
and over-expression of FGFR1 simply allow cells to respond toeven small amounts of growth factors in the culture medium
rather than these cells become truly FGF-independent. Although
the exact mechanism of action is not clear, our results strongly
suggest that LRIT3 facilitates ER export of FGFR1, that FGFR1 exits
the ER not in a constitutive fashion, but in a regulated fashion, and
that LRIT3 modulates the FGFR-signaling pathway.
The LRIT3 mutations we have identiﬁed are inherited from the
clinicallyunaffectedparents of theprobands. Therefore, thesemuta-
tions alone are not sufﬁcient to cause the disease. Interestingly,
expressionof auto-activatedPDGFRa causesCS inmice [20]. In these
mice, PLC-c is hyper-phosphorylated. Furthermore, inhibitors of
PLC-c prevent the mineralization of synthetic bone matrix. Consis-
tent with this ﬁnding, osteoblasts isolated from Apert CS patients
(FGFR2 S252W) display up-regulation of PLC-c signaling [23]. These
results suggest that over-activationof PLC-c is involved inCS.We re-
port here that mutant LRIT3s stimulate the PLC-c branch of the
FGFR1 pathway. Perhaps, aberrant PLC-c signaling may contribute
to NSC in concert with yet undeﬁned phenotypic contributors.
To avoid modiﬁcations by Golgi enzymes, LRIT3 should con-
stantly stay in the ER or cycles between the ER and the cis-Golgi
rapidly. There are multiple possibilities regarding how a mutation
in LRIT3 affects PLC-c. One possibility is that mutant LRIT3s them-
Fig. 4. Functional consequences of the LRIT3 mutations. The T53M (T8M) mutation
of LRIT3 is a known single nucleotide polymorphism (rs181200721). T53M LRIT3
was used as a control. (A and B) LRIT3 and/or FGFR1 were transfected into HEK293
cells. Transfected cells were analyzed by immunoblotting. Expression and phos-
phorylation status of indicated molecules were examined in the absence (A) or
presence (B) of basic FGF1. A mouse monoclonal anti-LRIT3 antibody was used to
visualize LRIT3. Note that all LRIT3 variants increased Golgi-modifed forms of
FGFR1.
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fect of FGFR1. ER retained FGFR1 may aberrantly activate PLC-c.
Alternatively, mutant LRIT3s fail to assist FGFR1 folding, resulting
in misfolded FGFR1 that can constitutively activate PLC-c. It is also
possible that FGFR1-LRIT3 complex constitutively activates PLC-c
in cis-Golgi.
Our results, in combination with others, suggest that FGFRs are
regulated at various steps (i.e., the biosynthetic route and the
endocytic pathway). Multiple defects in these regulatory steps
may synergistically inﬂuence the FGFR-signaling pathway, leading
to skeletal diseases or cancer.
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